A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
A phase 2 trial of Alectinib, Entrectinib, Vemurafenib in non-small-cell lung cancer and small-cell lung cancer, run by Genentech, Inc., now recruiting.
Overview
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT04302025 by Genentech, Inc., with 99 participants planned, started 2020-11-06 and due to reach its primary completion in 2026-11-30. Interventions recorded: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C
Shares Alectinib, Entrectinib, Roche / Genentech, Small-cell lung cancer.
- TrialA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Alectinib, Atezolizumab, Roche / Genentech, Small-cell lung cancer.
- CompanyChugai Pharmaceutical
Shares Alectinib, Atezolizumab, Roche / Genentech, Non-small-cell lung cancer.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme
Shares Entrectinib, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Shares Cobimetinib, Atezolizumab, Roche / Genentech.
- PersonGrant McArthur
Shares Cobimetinib, Vemurafenib.
- TrialStudy to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [
Shares Atezolizumab, Roche / Genentech, Small-cell lung cancer, Non-small-cell lung cancer.